secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2024-08-28T23:59:59+00:00
Accession:  0001193125-24-208688
Event type: litigation
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma wins partial injunction against Avadel's Lumryz, ongoing royalty above 3.5%
--------------------------------------------------------------------------------

- On August 27, 2024, U.S. District Court granted Jazz's motion for permanent injunction against Avadel.
- Injunction prevents Avadel from seeking FDA approval or marketing Lumryz for idiopathic hypersomnia or other new indications.
- Avadel is enjoined from infringing Claim 24 of Jazz's '782 patent through February 2036, except for narcolepsy and existing patients.
- Court awarded Jazz an ongoing royalty for future narcolepsy Lumryz sales at a rate to be determined above 3.5%.
- Jazz previously won jury verdict finding '782 patent valid and damages for past Lumryz sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000119312524208688/0001193125-24-208688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000119312524208688/d886606d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-208688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer